Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Drake OBSnon-steroidal anti-inflammatory drugscontrolCOVID 19 hospitalizedNA
4205/4205 inconclusive
  • inconclusive 5 % decrease in deaths (PE)
Bruce OBSnon-steroidal anti-inflammatory drugscontrolCOVID 19 hospitalizedNA
54/1168 inconclusive
  • inconclusive 11 % decrease in deaths,deaths (time to event analysis only) (PE)
Wenxin
  ChiCTR2000031630.		 OBSCelecoxibcontrolCOVID 19 hospitalizedNA
36/7 suggested
  • suggested 92 % decrease in clinical deterioration
  • suggested 11.8-fold increase in clinical improvement
concentrations of PGE2 in urine samples of COVID-19 patients were significantly higher than that of healthy individuals (mean value is 170 ng/ml vs 18.8 ng/ml, p<0.01) and positively correlated with the progression of COVID-19.
Jeong OBSnon-steroidal anti-inflammatory drugscontrolCOVID 19 hospitalizedNA
354/1470 safety concern
  • statistically significant 65 % increase in clinical deterioration (PE)
  • statistically significant 87 % increase in cardiovascular or renal events

COVID-19 mild to moderate meta-analysis

Ravichandran
  CTRI/2021/05/033544		 RCTIndomethacinparacetamolCOVID-19 mild to moderatesome concern
103/107 suggested
  • suggested 98 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
Ravichandran OBSIndomethacinCOVID-19 mild to moderateNA
82/109 ongoing

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons